Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, open-label study. 40 patients will be followed for a
period of 12 months. All consented and enrolled patients will receive either 0.5mg or 2.0mg
of intravitreal ranibizumab injection.